VJHemOnc is committed to improving our service to you

ERIC 2020 | Next-generation sequencing in CLL

VJHemOnc is committed to improving our service to you

Richard Rosenquist

Richard Rosenquist, MD, PhD, Karolinska University Hospital, Solna, Sweden, discusses next-generation sequencing (NGS). Next-generation sequencing allows for more genes to be analyzed in chronic lymphocytic leukemia (CLL) research and has higher sensitivity. the European Research Initiative on CLL has a certification system for both Sanger sequencing and NGS and as more labs request certification for next-generation sequencing, it will become the new gold standard. Additionally, Prof. Rosenquist mentions the gene panel used at Karolinska University Hospital, which includes TP53, BTK and PLCγ2. This interview took place during the ERIC International Virtual Meeting 2020.

Transcript (edited for clarity)

So next-generation sequencing has enabled us to analyze lots of genes and also more genes at the same time. And in CLL, since we need to analyze for TP53 mutations, it has been a shift from Sanger sequencing to next-generation sequencing in order to detect TP53 mutations. Also, next-generation sequencing has a higher sensitivity compared to Sanger sequencing. And through ERIC, we have a certification system for both Sanger sequencing and for next-generation sequencing...

So next-generation sequencing has enabled us to analyze lots of genes and also more genes at the same time. And in CLL, since we need to analyze for TP53 mutations, it has been a shift from Sanger sequencing to next-generation sequencing in order to detect TP53 mutations. Also, next-generation sequencing has a higher sensitivity compared to Sanger sequencing. And through ERIC, we have a certification system for both Sanger sequencing and for next-generation sequencing. And we see that many labs are more and more certifying for next-generation sequencing. So it’s obvious that this technique will be the gold standard for the future. And here at Karolinska, we use a gene panel where TP53 is included. Also, we have included BTK and PLC gamma-2. So if the referring physician asks for resistance mutations, we can also give reply for these two genes.

Read more...

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter